
INTRODUCTION Panax ginseng C.A. Meyer is among the most extensively studied medicinal herbs, valued for its adaptogenic, immunomodulatory, antioxidant, anti-inflammatory, and neuroprotective properties. In traditional Chinese medicine (TCM), it is the principal Qi-tonifying herb (Renshen) and a key ingredient of classical formulas such as Si Jun Zi Tang, Sheng Mai San, and Shen Fu Tang. This narrative review provides an integrative, mechanism-oriented account of its phytochemistry, pharmacokinetics, pharmacology, clinical evidence, and safety. METHODS PubMed, Scopus, Web of Science, ScienceDirect, and Google Scholar were searched for English-language publications, emphasizing the past 10–15 years together with key foundational works. Records were screened in stages against predefined inclusion and exclusion criteria. Study quality was appraised qualitatively (CASP checklists; Cochrane Risk of Bias tool for randomized trials), and evidence was synthesized narratively. No review protocol was registered, and no data were pooled. RESULTS Ginsenosides, together with polysaccharides, polyacetylenes, flavonoids, and phenolic compounds, modulate the PI3K/Akt, AMPK, MAPK, NF-κB, and Nrf2 signaling pathways. Preclinical and, to a lesser extent, clinical evidence suggests benefits in metabolic disorders, cardiovascular disease, neurodegeneration, immune dysfunction, chronic inflammation, fatigue, and cancer. Oral absorption of ginsenosides is poor, but nanoparticle and liposome-based delivery systems have improved their bioavailability. Clinical studies generally report good tolerability and adjunctive efficacy. DISCUSSION Variability in extract standardization, dosage, and study quality limits definitive conclusions. Future research should prioritize standardized preparations, multicenter clinical trials, systems pharmacology, multi-omics, and artificial intelligence-assisted drug discovery. P. ginseng is a promising phytopharmaceutical linking TCM and modern pharmacology, with potential for chronic disease management within an integrative healthcare framework.
Background Mentha canadensis (Bohe, Herba Menthae, Wild Mint) belongs to the Lamiaceae family and has a long history of use in Traditional Chinese Medicine (TCM). It is an aromatic herb with diverse Chinese traditional therapeutic applications and is also used in food and beverage applications. Aims This study aimed to investigate the anticancer efficacy of the M. canadensis leaves methanolic extract (MCLME) using both in silico and In vivo assays. Methods Molecular docking and molecular dynamics simulations were carried out to elucidate the binding affinity between MCLME-derived phytochemicals and the anti-apoptotic protein Bcl-2. In vivo antineoplastic efficacy was assessed by analyzing the inhibition of EAC cell growth, survival duration, and tumor burden in tumor-bearing mice, hematological parameters, apoptotic morphology, and expression of apoptosis-related genes. Results Several bioactive compounds were identified in MCLME, and among them, CID 60157539 and CID 576686 exhibited favorable binding affinities for Bcl-2, with binding energies of −8.8 kcal/mol and −8.2 kcal/mol, respectively. This interaction could provide a stable protein–ligand complex with enhanced structural compactness and energetically favorable conformations supports their potential role as a Bcl-2 inhibitor and suggests that MCLME could be a potential source of anticancer agents. MCLME significantly inhibited EAC cell growth by 62.95% (p < 0.001) and 45.655% (p < 0.001) at doses of 200 mg/kg and 100 mg/kg, respectively. The lifespan of EAC-bearing mice was increased by 50.66%, and the tumor burden was reduced by 35.24% compared with control mice (200mg/kg; p < 0.001). Furthermore, MCLME restored blood parameters, including RBCs, WBCs, platelets, and hemoglobin, in EAC-bearing animals, suggesting potential resistance to tumor burden. MCLME-treated EAC cells exhibited membrane blebbing, chromatin condensation, and nuclear fragmentation (apoptotic features) under both light and fluorescence microscopy. DNA fragmentation also demonstrated that MCLME caused EAC cell death via apoptosis. Moreover, treatment induced upregulation of key pro-apoptotic genes (p53, Bax, caspase-9, and caspase-3) and suppressed expression of the anti-apoptotic gene Bcl-2 in treated mice. Conclusions Together, the findings of the present study show that M. canadensis might be a potential resource for cancer chemotherapy, which exhibits potential anticancer activity accompanied by a caspase-dependent pathway, thus, supporting traditional uses of the plant in various illnesses, including cancers.
Introduction The WHO recognizes Curcuma, including C. longa (Jianghuang in Traditional Chinese Medicine), as a widely used medicinal plant and a natural source of antioxidant and anti-inflammatory activity. However, its phytochemical complexity challenges quality assurance, as single markers like curcumin do not reflect overall bioactivity. Metabolomics and chemometrics offer a multivariate approach to identifying candidate markers associated with bioactivity. This systematic review evaluates how chemometrics has been used in Curcuma metabolomics studies to identify candidate compounds associated with antioxidant and anti-inflammatory activities. It assesses the methodological rigor of these workflows and the strength of evidence for each candidate, as a basis for future validation. Methods Following PRISMA 2020 guidelines and a PICO-structured protocol, we conducted literature searches in Scopus and PubMed through July 2026. Original English-language articles using metabolomic platforms (LC-MS, GC–MS, NMR) combined with multivariate chemometrics (PCA, PLS-DA/OPLS-DA, PLS-R/OPLS) and direct assessments of antioxidant or anti-inflammatory bioactivity were eligible. Screening was performed in Rayyan with independent duplicate review; extracted data were qualitatively synthesized and stratified by evidence level and identification confidence. Results Of the 957 records identified through searches in Scopus and PubMed, 12 primary research articles met the eligibility criteria and were included in the qualitative synthesis, yielding 50 candidate marker entries from 36 compounds. PCA was used for exploratory discrimination in most studies (11 of 12), followed by supervised approaches, including PLS-DA/OPLS-DA for classification, PLS-R/OPLS regression against bioactivity outcomes, or simple correlation analysis. Curcuminoids (primarily curcumin, demethoxycurcumin, and bisdemethoxycurcumin) and sesquiterpenoids (xanthorrhizol and germacrone) collectively accounted for 90.0% of the candidate markers and were the classes most frequently reported as associated with antioxidant and anti-inflammatory activities, alongside species-specific candidates such as zedoarol in C. xanthorrhiza. Evidence stratification showed that 76.0% of markers were supported solely by discriminative or correlative statistical evidence, whereas 24.0% were tested directly in experimental assays. Comprehensive chemometric validation (cross-validation, permutation testing, and R²/Q² reporting) was reported in 58.3% of studies (7/12), but only 16.7% (2/12) reported using QC samples during acquisition. None used an external test set. Discussion Metabolomics integrated with chemometrics addresses Curcuma’s biochemical complexity and supports a potential shift toward multi-marker quality assurance based on bioactivity-correlated candidates, though most still require independent experimental validation before they can be considered validated quality-control markers. However, the current evidence base remains constrained by inconsistencies in model validation and identification rigor across studies. Future research should prioritize experimental validation of statistically derived markers using human-relevant models, standardized reporting of chemometric validation, and scalable, industry-compatible analytical workflows.